ISRCTN49221770已完成不适用
A Randomised Study of MVP (Mitomycin-C, Vinblastine and Moderate Dose Cisplatin) Three versus Six Cycles in Advanced Non-Small Cell Lung Cancer
The Royal Marsden NHS Foundation Trust (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histological evidence of non-small cell lung cancer
- •2. Stage IIIb or IV disease not eligible for neoadjuvant chemotherapy and/or radical radiotherapy
- •3. Performance status <2 (Zubrod-Eastern Cooperative Oncology Group [ECOG]-World Health Organisation [WHO] scale)
- •4. Adequate renal, bone marrow, and lung function tests unless due to metastatic disease
- •5. Patients must already have achieved symptom relief after three cycles of MVP chemotherapy
- •6. No uncontrolled infection
- •7. No previous conventional chemotherapy prior to MVP. One prior phase I/II new drug is allowed
- •8. No medical contraindications to treatment protocols
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
A randomised study of Mitomycin, Vinblastine and Platinum (cisplatin) (MVP) three versus six cycles in advanced Non-Small Cell Lung Cancer (NSCLC)ung (non-small cell) cancerLung (non-small cell) cancerCancerISRCTN57675565Cancer Research UK (CRUK) (UK)308
尚未招募
3 期
Role of pre procedure mitomycin C inside the bladder in treatment in patients with recurrent Non invasive bladder cancerCTRI/2024/05/067430AIIMS bhubaneswar
招募中
4 期
Comparisonof the use of Mitomycin C and Triamcinolone in the management of esophageal strictures inchildren which are refractory to standard managementCTRI/2019/01/017262Rishi Bolia
已完成
不适用
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) InfectionCytomegalovirus InfectionGlioblastoma MultiformeNCT00400322Karolinska Institutet42
招募中
2 期
Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcomarhabdomyosarcomaJPRN-UMIN000020891Japan Rhabdomyosarcoma Study Group22